Press Releases

InVivo Therapeutics Announces Uplisting to Nasdaq

Published: April 16, 2015

CAMBRIDGE, Mass. (April 16, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that its common stock has been approved to begin trading on The Nasdaq Capital Market. The company’s common stock will begin trading under the symbol “NVIV” at the opening of trading on Friday, April 17, 2015. “We are pleased to reach this important corporate milestone. InVivo has made significant progress spanning all areas of the organization over the last year and uplisting to Nasdaq will allow us to communicate this progress with a broader audience. We are now better positioned to enhance stock liquidity and attract institutional investors, […]

View Article
InVivo Therapeutics Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ

Published: April 8, 2015

CAMBRIDGE, Mass. (April 8, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the  implementation of its previously disclosed 1-for-4 reverse stock split as of today, April 8, 2015, a key step in preparation for its planned uplisting to the NASDAQ Capital Market. “We are pleased to have completed the reverse stock split in preparation for uplisting, which we believe will result in better liquidity and attract additional investors to our company. Although we cannot make any assurances, we are hopeful NASDAQ will accept our listing application and that we will begin trading on the exchange in the imminent future,” said […]

View Article
InVivo Therapeutics Announces New Clinical Trial Site for Neuro-Spinal Scaffold

Published: April 1, 2015

CAMBRIDGE, Mass. (April 1, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that UC Davis Medical Center in Sacramento, CA has been added as a clinical site in the company’s ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). The medical center serves a 65,000 square-mile territory that includes 33 counties and 6 million residents across northern and central California. Mark Perrin, InVivo’s CEO and Chairman, said, “I am pleased with this newest addition to InVivo’s ongoing clinical study of our Neuro-Spinal Scaffold. We now have ten clinical sites open to enroll the […]

View Article
InVivo Therapeutics Announces University of Kansas Medical Center as New Site for Neuro-Spinal Scaffold Clinical Trial

Published: March 30, 2015

CAMBRIDGE, Mass. (March 30, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the University of Kansas Medical Center in Kansas City, KS has been added as a clinical site in the company’s ongoing Investigational Device Exemption (IDE) pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Paul Arnold, MD, Professor of Neurosurgery and Vice Chair of Research, has been named Principal Investigator at the site. “We look forward to participating in this exciting pilot study of an innovative device that is targeted at addressing the huge unmet medical need in the treatment of acute […]

View Article
InVivo Therapeutics Exhibiting at 66th Southern Neurosurgical Society Annual Meeting

Published: March 27, 2015

CAMBRIDGE, Mass. (March 27, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the company is exhibiting at the 66th Southern Neurosurgical Society (SNS) Annual Meeting being held in Naples, Florida on March 25-28, 2015. Tom Ulich, MD, InVivo’s Chief Scientific Officer, and Lorianne Masuoka, MD, InVivo’s Chief Medical Officer, are presenting intraoperative videos from the company’s ongoing Investigational Device Exemption (IDE) pilot study, which has enrolled two subjects thus far.  The videos provide an update to the neurosurgical community on the company’s investigational Neuro-Spinal Scaffold novel implantation techniques, which until InVivo’s pilot study, had never been performed in patients with […]

View Article
InVivo Therapeutics Announces Reopening of Enrollment for Subjects Three through Five for Anticipated Completion of Ongoing Pilot Trial

Published: March 26, 2015

CAMBRIDGE, Mass. (March 26, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the reopening of subject enrollment for the company’s ongoing Investigational Device Exemption (IDE) pilot study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. Barring significant safety issues, the final three subjects of this pilot trial will be enrolled concurrently and without mandatory safety hold between enrollment of each subject. To date, there have been no reported serious safety events related to the Neuro-Spinal Scaffold or the procedure to implant the Neuro-Spinal Scaffold with the study’s first and second subjects, and InVivo has been approved […]

View Article
InVivo Therapeutics Announces Keck Hospital of University of Southern California as New Site for Neuro-Spinal Scaffold Clinical Trial

Published: March 25, 2015

CAMBRIDGE, Mass. (March 25, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Keck Hospital of University of Southern California (USC) in Los Angeles, CA has been added as a clinical site in the company’s ongoing Investigational Device Exemption (IDE) pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). The Keck Hospital of USC is a 401-bed acute care hospital for the Keck Medical Center of USC, a system that comprises more than 500 faculty physicians. Patrick Hsieh, MD, Director of Neurosurgery Spine Program and Associate Professor of Neurological Surgery, has been named Principal […]

View Article
InVivo Therapeutics Announces Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ

Published: March 24, 2015

CAMBRIDGE, Mass. (Mar 24, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that its Board of Directors has approved a 1-for-4 reverse stock split of its issued and outstanding common stock in preparation for its planned uplisting to the NASDAQ Capital Market. The company anticipates the reverse stock split to become effective and its common stock to begin trading on a post-split basis at the open of trading on April 8, 2015, contingent upon approval from the Financial Industry Regulatory Authority (FINRA). “The execution of this reverse split represents an important step in achieving an essential corporate objective – […]

View Article
InVivo Therapeutics Reports 2014 Year End Financial Results and Business Update

Published: March 11, 2015

CAMBRIDGE, Mass. (March 11, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2014.

Mark Perrin, InVivo’s CEO and Chairman, said, “2014 was a momentous year for InVivo in every sense of the word. It’s gratifying to look back on how much we accomplished last year and exciting to see the trajectory the company is following. We are in a much better position to execute on our corporate goals than we were only 15 months ago and are significantly closer to achieving our mission: to redefine the life of the spinal cord injury patient. I’m pleased with how we’ve advanced as a company and am very much looking forward to a fruitful 2015.” […]

View Article
InVivo Therapeutics Announces Froedtert & the Medical College of Wisconsin as New Clinical Trial Site for Neuro-Spinal Scaffold

Published: February 23, 2015

CAMBRIDGE, Mass. (Feb 23, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Froedtert & the Medical College of Wisconsin (MCW) Froedtert Hospital in Milwaukee, WI has been added as a clinical site in the company’s ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Froedtert Hospital houses the only adult Level 1 trauma center in eastern Wisconsin and receives referred spinal cord injury patients from Wisconsin, northern Illinois, and northern Michigan. Shekar Kurpad, MD, PhD, professor of neurosurgery at MCW and director of the Spinal Cord Injury Center and Spine Surgery Fellowship at Froedtert Hospital, has been named Principal Investigator at the site […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.